NASDAQ:CVET

Covetrus Stock Forecast, Price & News

$25.45
-0.07 (-0.27 %)
(As of 07/29/2021 12:00 AM ET)
Add
Compare
Today's Range
$25.45
$25.83
50-Day Range
$23.99
$28.27
52-Week Range
$18.74
$40.78
Volume199,087 shs
Average Volume707,153 shs
Market Capitalization$3.48 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.05
30 days | 90 days | 365 days | Advanced Chart
Receive CVET News and Ratings via Email

Sign-up to receive the latest news and ratings for Covetrus and its competitors with MarketBeat's FREE daily newsletter.


Covetrus logo

About Covetrus

Covetrus, Inc. engages in developing technologies and services for animal health industry. It also provides products, software, and services to help drive improved patient health, strong client relationships and successful financial outcomes for veterinary professionals. The firm geographically operates through the segments: North America, Europe and Asia Pacific (APAC) & Emerging Markets. The company was founded by Benjamin J. Shaw in 2014 and is headquartered in Portland, ME.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.97 out of 5 stars

Computer And Technology Sector

256th out of 1,650 stocks

Drug Stores & Proprietary Stores Industry

4th out of 16 stocks

Analyst Opinion: 3.4Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 1.9 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Covetrus (NASDAQ:CVET) Frequently Asked Questions

Is Covetrus a buy right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Covetrus in the last twelve months. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Covetrus stock.
View analyst ratings for Covetrus
or view top-rated stocks.

What stocks does MarketBeat like better than Covetrus?

Wall Street analysts have given Covetrus a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Covetrus wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Covetrus' next earnings date?

Covetrus is scheduled to release its next quarterly earnings announcement on Tuesday, August 10th 2021.
View our earnings forecast for Covetrus
.

How were Covetrus' earnings last quarter?

Covetrus, Inc. (NASDAQ:CVET) released its earnings results on Thursday, May, 6th. The company reported $0.16 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $0.12 by $0.04. The firm earned $1.10 billion during the quarter, compared to analysts' expectations of $1.08 billion. Covetrus had a negative net margin of 0.02% and a positive trailing twelve-month return on equity of 6.38%.
View Covetrus' earnings history
.

How has Covetrus' stock been impacted by COVID-19 (Coronavirus)?

Covetrus' stock was trading at $9.04 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, CVET stock has increased by 181.5% and is now trading at $25.45.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for CVET?

5 brokerages have issued 12-month price targets for Covetrus' shares. Their forecasts range from $20.00 to $48.00. On average, they expect Covetrus' stock price to reach $32.60 in the next twelve months. This suggests a possible upside of 28.1% from the stock's current price.
View analysts' price targets for Covetrus
or view top-rated stocks among Wall Street analysts.

Who are Covetrus' key executives?

Covetrus' management team includes the following people:
  • Benjamin C. Wolin, President, Chief Executive Officer & Director
  • Matthew J. Foulston, Chief Financial Officer
  • Steve Palmucci, Global Chief Information Officer
  • Georgina Wraight, President-Global Technology Solutions & EVP
  • Laura J. Phillips, Chief Accounting Officer & Vice President

What is Benjamin Wolin's approval rating as Covetrus' CEO?

25 employees have rated Covetrus CEO Benjamin Wolin on Glassdoor.com. Benjamin Wolin has an approval rating of 89% among Covetrus' employees.

Who are some of Covetrus' key competitors?

What other stocks do shareholders of Covetrus own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Covetrus investors own include Pfizer (PFE), NVIDIA (NVDA), Advanced Micro Devices (AMD), AT&T (T), Activision Blizzard (ATVI), The Boeing (BA), Chegg (CHGG), Enphase Energy (ENPH), Enterprise Products Partners (EPD) and Livongo Health (LVGO).

What is Covetrus' stock symbol?

Covetrus trades on the NASDAQ under the ticker symbol "CVET."

Who are Covetrus' major shareholders?

Covetrus' stock is owned by many different retail and institutional investors. Top institutional investors include Private Management Group Inc. (0.16%), State of Alaska Department of Revenue (0.05%), Moody Lynn & Lieberson LLC (0.02%) and Harel Insurance Investments & Financial Services Ltd. (0.01%). Company insiders that own Covetrus stock include Anthony C Jr Providenti, Benjamin Shaw, Benjamin Wolin, David Stuart Hinton, Dustin Finer, Edward Mcnamara, Erin Powers Brennan, Georgina Wraight, Herbert Virgin, Laura J Phillips, Michael Ellis and Timothy Ludlow.
View institutional ownership trends for Covetrus
.

Which institutional investors are selling Covetrus stock?

CVET stock was sold by a variety of institutional investors in the last quarter, including Harel Insurance Investments & Financial Services Ltd., Moody Lynn & Lieberson LLC, and Private Management Group Inc.. Company insiders that have sold Covetrus company stock in the last year include Anthony C Jr Providenti, Benjamin Wolin, David Stuart Hinton, Dustin Finer, Edward Mcnamara, Georgina Wraight, Herbert Virgin, Laura J Phillips, Michael Ellis, and Timothy Ludlow.
View insider buying and selling activity for Covetrus
or view top insider-selling stocks.

Which institutional investors are buying Covetrus stock?

CVET stock was purchased by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue. Company insiders that have bought Covetrus stock in the last two years include Benjamin Shaw, and Erin Powers Brennan.
View insider buying and selling activity for Covetrus
or or view top insider-buying stocks.

How do I buy shares of Covetrus?

Shares of CVET can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Covetrus' stock price today?

One share of CVET stock can currently be purchased for approximately $25.45.

How much money does Covetrus make?

Covetrus has a market capitalization of $3.48 billion and generates $4.34 billion in revenue each year. The company earns $-19,000,000.00 in net income (profit) each year or $0.59 on an earnings per share basis.

How many employees does Covetrus have?

Covetrus employs 5,657 workers across the globe.

What is Covetrus' official website?

The official website for Covetrus is www.henryscheinvet.com.

Where are Covetrus' headquarters?

Covetrus is headquartered at 7 CUSTOM HOUSE STREET, PORTLAND ME, 04101.

How can I contact Covetrus?

Covetrus' mailing address is 7 CUSTOM HOUSE STREET, PORTLAND ME, 04101. The company can be reached via phone at (888) 280-2221 or via email at [email protected]


This page was last updated on 7/29/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.